Items Tagged with 'Pfizer Inc. (NYSE: PFE)'

ARTICLES

PFE Complete $11.85 billion Sale

Pfizer Completes Sale of Nutrition Business to Nestlé

On November 30, Pfizer Inc. (NYSE: PFE) announced that it has completed the sale of its Nutrition business to Nestlé for $11.85 billion in cash, following the conclusion of the required regulatory process in most markets.


Read More
PFE Announces Revenues of $14.0 billion

Pfizer Reports Third-Quarter 2012 Results

On November 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2012. Third-quarter 2012 revenues were $14.0 billion, a decrease of 16% compared with $16.6 billion in the year-ago quarter, which reflects an operational decline of $1.9 billion, or 12%, and the unfavorable impact of foreign exchange of $699 million, or 4%.


Read More
PFE Obtains FDA Approval for Lyrica

Pfizer FDA Approval Received

On June 21, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Lyrica® (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.


Read More
Pfizer Buys Vitamin C Icon

Pfizer Acquisition Announced

On February 27, 2012, Pfizer Inc. (NYSE:PFE) announced the acquisition of privately-held Alacer Corp....


Read More

Pfizer Recall Announced

On February 1, 2012, Pfizer Inc. (NYSE: PFE) announced that it has voluntarily recalled 14 lots of Lo/Ovral®-28 (norgestrel and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic) for customers in the U.S. market.


Read More

Pfizer FDA Approval Received

On January 27, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.


Read More

Pfizer Trial Results Announced

On January 17, 2012, Medivation, Inc.(NASDAQ: MDVN) and Pfizer Inc. (NYSE: PFE) announced results from the CONCERT trial, which is a Phase 3 trial that evaluated dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer’s disease.


Read More

Pfizer FDA Approval Granted

On December 30, 2011, Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company’s pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. 


Read More

Learn George Putnam's Turnaround Secrets

stock picks

Turnaround Investing Blog

Turnaround Investing Blog

Don't Make Too Much of Price History

It can be tempting to look at a depressed stock and think, “it used to trade at 40 and now it’s at 8 – therefore it must be a bargain.” Unfortunately, the fact that a stock once traded at a higher price does not guarantee that it will ever get back there. One big reason that a stock trades so much lower than before: its earnings potential or assets have deteriorated. Without some fundamental improvement, the share price will continue to lag, or worse. Read More.

Market-Beating Profit: The 200+ Club

Turnaround stocks present a unique opportunity for savvy investors to buy in at bargain prices. Take a look at this list of just a few of our purchase recommendations that have realized a return rate of 200% or better:

* Bristow remains an our active purchase recommendation, currently as a "Hold," and 1,928% stock profit is as of 8/11/16.

Retail Turnaround Trio

value stock

x

MoneyShow.com interviewed George to learn more about his favorite value stock picks for today's market. In "Retail Turnaround Trio," Steve Halpern highlights three of The Turnaround Letter's recently-profiled retailers: JWN, TIF and SPLS.

 

Putnam notes, "Well the retailing sector is undergoing very fundamental change as people move away from the bricks and mortar mall doors to buying more and more online but that's not going to wipe out all of the old-fashioned retailers. Starting the middle of 2015, investors just moved away from retailers en masse and a number of them are trading at about half the level they were a year ago. We thought some of the higher quality names that definitely will be survivors looked interesting."

 

Learn more about these three retail stocks poised for a turnaround.